Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Chimerix, Inc. (NASDAQ:CMRX) Q1 2024 Earnings Call Transcript May 1, 2024 Chimerix, Inc. misses on earnings expectations. Reported EPS is $-0.25 EPS, expectations were $-0.21. Chimerix, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies and gentlemen, […]
Insights into Chimerix Inc's financial health, strategic progress in clinical trials, and future plans from the latest earnings call.
Q1 2024 Chimerix Inc Earnings Call
– Dordaviprone (ONC201) ACTION Study Progressing; Reiterates Expectations for Interim Overall Survival (OS) Data in 2025 and Final OS Data in 2026 – – No Dose Limiting Toxicity in ONC206 Phase 1 Studies to Date, Preliminary Phase 1 Safety and Pharmacokinetic (PK) Data Expected This Summer – – Company to Advance Dordaviprone in Provisional Registration Process Following Positive Interaction with Therapeutic Goods Administration (TGA) in Australia – – Conference Call at 8:30 a.m. ET Today – DURHAM
DURHAM, N.C., April 24, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Wednesday, May 1, 2024 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2024, and to provide a business overview. To access the live conference call, please dial (646)
DURHAM, N.C., April 16, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX) today announced that on April 10, 2024, the Compensation Committee of Chimerix’s Board of Directors granted inducement awards to four new employees of non-statutory stock options to purchase up to a total of 223,000 shares of Chimerix’s common stock. The Compensation Committee of Chimerix’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing rule
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Veteran Industry Executive Brings More Than 35 Years of Corporate Strategy ExperienceDURHAM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the appointment of Marc D. Kozin as the newest member of the Company’s Board of Directors. In addition, Patrick Machado has announced his retirement from the Chimerix Board effe
Chimerix ( NASDAQ:CMRX ) Full Year 2023 Results Key Financial Results Net loss: US$82.1m (down by 148% from US$172.2m...
Chimerix, Inc. (NASDAQ:CMRX) Q4 2023 Earnings Call Transcript February 29, 2024 Chimerix, Inc. beats earnings expectations. Reported EPS is $-0.2, expectations were $-0.23. CMRX isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies and gentlemen, and welcome to […]